Ken Griffin Lyell Immunopharma, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,900 shares of LYEL stock, worth $29,609. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,900

Previous 7,700 62.34%

Holding current value

$29,609

Previous $4,000 75.0%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.48 - $0.74 $361,013 - $556,562	752,112 Added 20.03%	4,506,857 $2.43 Million
Q4 2024 Feb 14, 2025	BUY	$0.59 - $1.48 $2.21 Million - $5.55 Million	3,752,968 Added 211196.84%	3,754,745 $2.4 Million
Q3 2024 Nov 14, 2024	SELL	$1.13 - $1.88 $309,556 - $515,014	-273,944 Reduced 99.36%	1,777 $2,000
Q2 2024 Aug 14, 2024	SELL	$1.3 - $3.01 $663,809 - $1.54 Million	-510,623 Reduced 64.94%	275,721 $399,000
Q1 2024 May 15, 2024	SELL	$1.71 - $3.07 $4.6 Million - $8.26 Million	-2,690,884 Reduced 77.39%	786,344 $1.75 Million
Q4 2023 Feb 14, 2024	BUY	$1.39 - $2.35 $3.79 Million - $6.42 Million	2,730,085 Added 365.4%	3,477,228 $6.75 Million
Q3 2023 Nov 14, 2023	BUY	$1.45 - $3.35 $1.02 Million - $2.37 Million	706,419 Added 1734.65%	747,143 $1.1 Million
Q2 2023 Aug 14, 2023	SELL	$1.89 - $3.86 $34,961 - $71,402	-18,498 Reduced 31.24%	40,724 $129,000
Q1 2023 May 15, 2023	BUY	$1.97 - $3.58 $83,031 - $150,889	42,148 Added 246.85%	59,222 $139,000
Q4 2022 Feb 14, 2023	BUY	$2.78 - $8.09 $47,465 - $138,128	17,074 New	17,074 $59,000

Others Institutions Holding LYEL

# of Institutions

117

Shares Held

175M

Call Options Held

2.9K

Put Options Held

View Full List

About Lyell Immunopharma, Inc.

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $2.53B
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

More about LYEL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account